2-amino-N-(1H-imidazol-2-yl)-3-nitro-benzamide | 910122-44-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-N-(1H-imidazol-2-yl)-3-nitro-benzamide
• 英文别名: 2-amino-N-(1H-imidazol-2-yl)-3-nitrobenzamide
• CAS: 910122-44-0
• 化学式: C10H9N5O3
• 分子量: 247.21
• InChiKey: PWRJLNPGVGCTSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氨基-3-硝基苯甲酸 、 2-(1h-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 2-氨基咪唑硫酸盐 、 sodium hydroxide 在 水 、 乙酸乙酯 作用下， 以 N,N-二甲基甲酰胺 、 Brine 为溶剂， 反应 3.17h， 以to provide 5.3 g (75%) of 2-amino-N-(1H-imidazol-2-yl)-3-nitro-benzamide as a yellow solid的产率得到2-amino-N-(1H-imidazol-2-yl)-3-nitro-benzamide
  参考文献：
  名称：

  Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors

  摘要：

  本发明涉及抑制β-淀粉样前体蛋白剪切酶（BACE）的苯并咪唑化合物，其可用于治疗或预防BACE参与的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗BACE参与的这些疾病中使用这些化合物和组合物。

  公开号：

  US20140066477A1

文献信息

• Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
  申请人：Mjalli M.M. Adnan

  公开号：US20060223849A1

  公开（公告）日：2006-10-05

  The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.

  本发明涉及一种抑制β-淀粉样前体蛋白剪切酶（BACE）的苯并咪唑化合物，该化合物可用于治疗或预防BACE参与的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗BACE参与的这些疾病中使用这些化合物和组合物的用途。
• Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors
  申请人：Mjalli Adnan M.M.

  公开号：US20110065713A1

  公开（公告）日：2011-03-17

  The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.

  本发明涉及一种抑制 β-淀粉样前体蛋白裂解酶（BACE）的苯并咪唑化合物，该化合物可能在治疗或预防包括阿尔茨海默病在内的与BACE有关的疾病中有用。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗BACE参与的这类疾病中使用这些化合物和组合物。
• Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors
  申请人：High Point Pharmaceuticals, LLC

  公开号：US07893267B2

  公开（公告）日：2011-02-22

  The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.

  本发明涉及一种抑制β-淀粉样前体蛋白裂解酶（BACE）的苯并咪唑化合物，可用于治疗或预防BACE参与的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗BACE参与的这些疾病中使用这些化合物和组合物。
• Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
  申请人：High Point Pharmaceuticals, LLC

  公开号：EP2457901A1

  公开（公告）日：2012-05-30

  The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.

  本发明涉及抑制β位淀粉样前体蛋白切割酶（BACE）的苯甲唑化合物，这些化合物可用于治疗或预防BACE参与的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及 BACE 的此类疾病中的用途。
• BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS
  申请人：High Point Pharmaceuticals, LLC

  公开号：EP1863771B1

  公开（公告）日：2012-11-07